Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase (WRN) ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Elon Musk's brain-computer interface startup Neuralink secured $650 million in series E funding to expand patient access to ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...